Luna, 2143 ES. Twelve years after the interview that first introduced most of the system to her work, Dr. Sofia Russo, still lead researcher on Dome 4’s hibernation and cryopreservation program, announced this week that recruitment is open for the program’s first human cryosleep trials. Luna Interplanetary News spoke with her again — the same outlet, the same caution she was known for in 2131, considerably more data behind her this time.
LIN: Last time we spoke, you told our readers you’d be skeptical of anyone claiming human trials were close. Was that you managing expectations, or did you genuinely not expect to be here in twelve years?
Russo: Some of both, honestly, but I’ll correct something in your question — it wasn’t just time and repetition, and I don’t want to undersell what actually moved this. In 2131 we were capped by cryoprotectant clearance, not by vitrification stability. We could keep a subject vitrified indefinitely; we couldn’t reliably get one back past roughly two years without doing damage during the wash. That changed in 2141, when Dr. Elin Kowalczyk’s group at Dome 4 identified an enzyme in our own archived xenobiology library — Enceladus in origin, believe it or not — that clears our cryoprotectant compounds far faster than passive perfusion ever could, once mirror-synthesized into something that actually works on human tissue. That’s a Dome 4 chirality toolkit that’s existed since 2130; it just hadn’t been pointed at this problem yet. We had four subjects banked at four, five, six, and eight years, waiting specifically for a revival method that could handle them. Kowalczyk’s enzyme is what revived them, successfully, within weeks of validation. We’ve since pushed to ten. Every one of them alive, healthy by every longitudinal measure we track, and recognizably themselves behaviorally. Ten years was the number I needed before I was willing to say “human trials” out loud rather than “human trials, eventually” — but I want to be clear that the number exists because of a specific piece of work, not because we just waited long enough.
LIN: Walk us through what recruitment actually looks like.
Russo: We’re opening four tiers, by duration: one year, two years, five years, and ten. Every applicant goes through a full informed consent process — and I want to stress that word, informed, because we walk each candidate through exactly what we do and don’t know at the human scale before they’re allowed to sign anything. This is not the twenty years of chimpanzee data extrapolated with confidence. It’s twelve years of primate data and zero years of human data, about to become some years of human data.
LIN: What does the program actually offer people willing to take that risk?
Russo: Full insurance coverage for the duration of participation, covering the trial itself and any post-revival complications we identify as related. Compensation structure differs by tier — one- and two-year participants receive monthly payments for the duration of dormancy, disbursed to whatever account or beneficiary they designate going in. Five- and ten-year participants move to an annual disbursement instead — fewer payments, larger amounts, structured that way mostly for administrative sanity on our end over that kind of timeframe. In both cases, compensation continues regardless of outcome, and the insurance is what covers the outcome itself.
LIN: Regardless of outcome. That’s worth sitting with for a second.
Russo: It should be. I’m not going to sell this to your readers as risk-free because it isn’t, and anyone recruiting for a first human cohort who tells you otherwise shouldn’t be running the program. The chimpanzee data gives me genuine confidence, not certainty. That’s exactly why informed consent isn’t a formality here — it’s the center of how this is being run.
LIN: Who’s actually applying, so far?
Russo: Wider range of people than I expected, honestly. Some of it’s what you’d guess — people interested in the frontier, people who’d like to see further out than their own lifetime lets them. Some of it’s more practical: terminal patients looking at this as a different kind of long shot than the ones currently available to them, which is a conversation our ethics board has spent a great deal of time on, precisely because it’s not a population you want volunteering for the wrong reasons.
LIN: Last time, I asked you whether a task like this eventually needs something with broader adaptive judgment than a narrow monitoring system — meaning CAI, though I didn’t say the name directly, and you told me you weren’t the person qualified to answer where that line sits legally. Are you any more qualified to answer it now?
Russo: [laughs] You kept that quote. Fair enough. The honest update is: our monitoring architecture is more capable than it was in 2131, and some of that capability sits closer to CAI’s general reasoning than the narrow rewarming and perfusion controllers we used on the first chimpanzee. I still don’t make the call on what that means for oversight authority — that’s a legal and governance question, not a medical one, and it’s above where I sit. What I can tell you is that every threshold flag in this trial still routes to a human physician before any irreversible action is taken. Whether that stays true at ten years, unattended, decades from now, on a voyage rather than a monitored facility on Luna — I still don’t know, and I still don’t think it’s my question to answer.
LIN: A voyage. You’re referring to something specific.
Russo: I’m being careful not to overclaim a connection that isn’t formally established. What I’ll say is that people ask me constantly whether this program exists because of the Ark, and the honest answer is: this program exists because Dome 4 has been doing hibernation research since long before anyone announced a generation ship, and it would keep existing if the Ark were cancelled tomorrow. Whether the two eventually intersect is a question for people with a very different job than mine.
LIN: Dr. Russo, thank you again.